HK1209642A1 - Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea - Google Patents

Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea Download PDF

Info

Publication number
HK1209642A1
HK1209642A1 HK15110497.0A HK15110497A HK1209642A1 HK 1209642 A1 HK1209642 A1 HK 1209642A1 HK 15110497 A HK15110497 A HK 15110497A HK 1209642 A1 HK1209642 A1 HK 1209642A1
Authority
HK
Hong Kong
Prior art keywords
ylethyl
benzothiazol
pyridazin
sulfanyl
triazolo
Prior art date
Application number
HK15110497.0A
Other languages
English (en)
Chinese (zh)
Inventor
Jean-René Authelin
Sylvie ASSADOURIAN
Tsiala Benard
Hélène GOULAOUIC
Amandine MATHIEU
Maria-Teresa Peracchia
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HK1209642A1 publication Critical patent/HK1209642A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HK15110497.0A 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea HK1209642A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305840.6 2012-07-12
EP12305840 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (en) 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Publications (1)

Publication Number Publication Date
HK1209642A1 true HK1209642A1 (en) 2016-04-08

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110497.0A HK1209642A1 (en) 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Country Status (25)

Country Link
US (1) US20150119391A1 (enExample)
EP (1) EP2872119A1 (enExample)
JP (1) JP2015525754A (enExample)
KR (1) KR20150030761A (enExample)
CN (1) CN104470500A (enExample)
AR (1) AR091727A1 (enExample)
AU (1) AU2013288676A1 (enExample)
BR (1) BR112015000497A2 (enExample)
CA (1) CA2878500A1 (enExample)
CL (1) CL2015000074A1 (enExample)
CO (1) CO7160069A2 (enExample)
CR (1) CR20150005A (enExample)
EA (1) EA201590199A1 (enExample)
HK (1) HK1209642A1 (enExample)
IL (1) IL236662A0 (enExample)
IN (1) IN2015KN00075A (enExample)
MA (1) MA37753B1 (enExample)
MX (1) MX2015000532A (enExample)
PH (1) PH12015500060A1 (enExample)
SG (1) SG11201500123XA (enExample)
TN (1) TN2015000011A1 (enExample)
TW (1) TW201402121A (enExample)
UY (1) UY34909A (enExample)
WO (1) WO2014009500A1 (enExample)
ZA (1) ZA201500129B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544083A (ja) * 2021-12-15 2024-11-27 シルラジェン，インコーポレイテッド 修飾ベータ－シクロデキストリンを含む医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
JP4817068B2 (ja) * 2003-01-14 2011-11-16 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド 全身性エリテマトーデスの治療のためのペプチドの非経口製剤
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CA2716720A1 (en) * 2008-02-28 2009-09-03 Takeda Pharmaceutical Company Limited Pharmaceutical composition
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
AR091727A1 (es) 2015-02-25
JP2015525754A (ja) 2015-09-07
IL236662A0 (en) 2015-02-26
KR20150030761A (ko) 2015-03-20
TN2015000011A1 (en) 2016-06-29
CN104470500A (zh) 2015-03-25
MA37753A2 (fr) 2016-06-30
PH12015500060A1 (en) 2015-03-02
MX2015000532A (es) 2015-05-15
SG11201500123XA (en) 2015-02-27
UY34909A (es) 2013-11-29
WO2014009500A1 (en) 2014-01-16
IN2015KN00075A (enExample) 2015-07-31
ZA201500129B (en) 2015-12-23
BR112015000497A2 (pt) 2017-06-27
CA2878500A1 (en) 2014-01-16
CL2015000074A1 (es) 2015-06-12
US20150119391A1 (en) 2015-04-30
MA37753A3 (fr) 2018-05-31
EA201590199A1 (ru) 2015-05-29
MA37753B1 (fr) 2019-04-30
CO7160069A2 (es) 2015-01-15
EP2872119A1 (en) 2015-05-20
CR20150005A (es) 2015-04-06
TW201402121A (zh) 2014-01-16
AU2013288676A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
HK1215253A1 (zh) 作为激酶抑制剂的吡咯并嘧啶化合物
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
WO2015009726A3 (en) Medical uses of cd38 agonists
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
HK1209642A1 (en) Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
TN2019000114A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
EP3344625A4 (en) THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE
MX2015007054A (es) Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
HK1190406A1 (zh) 双环pkm2激活剂
NZ629459A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ622728A (en) Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)